Radiopharmaceutical developer Navidea Biopharmaceuticals reported a decline in revenues and an increase in net losses for its second quarter and first half of 2022.
Net revenues for the second quarter (end-June 30) were $57,000, compared with $261,000 for the same period last year. Navidea attributed lower revenues to the repayment of 2021 debts that were written off in 2015. Net revenues for the first half of the year were $57,000, compared with $385,000 in 2021.
The company sustained higher net losses for both the quarter and the first half of the year compared with 2021: $3 million versus $2.7 million in the second quarter and $6 million versus $5.6 million in the first half of the year, it said.
